Amarin (NASDAQ:AMRN) will sponsor a conference call on Monday, April 13, in 4:30 pm ET to supply preliminary Q1 results and also to upgrade its operations, such as its projected appeal of this adverse patent linked to Vascepa (icosapent ethyl).
Present consensus is a loss/share of ($0. 09) on earnings of 129M.
exemptions 1 percent later.
Facebook Comments